Bococizumab
- CAS No.
- 1407495-02-6
- Chemical Name:
- Bococizumab
- Synonyms
- Bococizumab;RN316|||PF-04950615;Bococizumab 6.17mg/ml;Bococizumab (anti-PCSK9);Research Grade Bococizumab;Research Grade Bococizumab(DHJ24004)
- CBNumber:
- CB68080899
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 45M75JVK38 |
Bococizumab Chemical Properties,Uses,Production
Uses
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].
in vivo
Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2].
| Animal Model: | Pregnant Sprague-Dawley (SD) rats[1] |
| Dosage: | 0, 10, 30, and 100 mg/kg |
| Administration: | Intravenous injection (i.v.) |
| Result: | Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters. |
References
[1] Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505. DOI:10.1253/circj.CJ-16-1310
[2] Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70. DOI:10.1016/j.yrtph.2015.08.007
Bococizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Bococizumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32433 | 58 |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 12952 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 71826 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| DC Chemicals | 021-8447131 13564518121 | doncunbiosci@gmail.com | China | 545 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24989 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9868 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 6262 | 58 |
View Lastest Price from Bococizumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-10-03 | Bococizumab
1407495-02-6
|
US $347.00-1390.00 / mg | 97.7% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Bococizumab
1407495-02-6
- US $347.00-1390.00 / mg
- 97.7% (SEC-HPLC)
- TargetMol Chemicals Inc.
